A 63-year-old patient taking eszopiclone (Lunesta) 2 mg nightly continues to have difficulty falling asleep, frequent awakenings, and restlessness; what is the next step in management?

Next Step: Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I)

The next step for this 63-year-old patient failing eszopiclone 2 mg is to initiate cognitive behavioral therapy for insomnia (CBT-I), which is the first-line treatment for chronic insomnia disorder and should have been started before or alongside medication. 1

Why CBT-I Should Be the Priority

The American College of Physicians provides a strong recommendation (moderate-quality evidence) that all adult patients should receive CBT-I as initial treatment for chronic insomnia disorder 1. This patient appears to have been started on pharmacotherapy without first attempting behavioral interventions, which represents a deviation from evidence-based guidelines.

CBT-I has demonstrated:

• Reduced sleep onset latency and wake after sleep onset
• Improved sleep efficiency and sleep quality
• Sustained benefits without tolerance
• Minimal to no harms (likely mild if any) 1

The therapy can be delivered through multiple modalities including in-person (individual or group), telephone, web-based modules, or self-help books, making it accessible even in primary care settings 1.

Medication Considerations While Pursuing CBT-I

Option 1: Increase Eszopiclone Dose (If CBT-I Unavailable or Adjunctive Therapy Needed)

If CBT-I alone is unsuccessful or unavailable, consider increasing eszopiclone to 3 mg nightly, which is FDA-approved and more effective for sleep maintenance 2. The FDA label specifically states: "Dosing can be initiated at or raised to 3 mg if clinically indicated, since 3 mg is more effective for sleep maintenance" 2.

Evidence supports this approach:

• Eszopiclone 3 mg significantly improved sleep maintenance, total sleep time, and sleep efficiency compared to 2 mg 3, 4
• In elderly patients (this patient is 63), eszopiclone 2 mg was effective for both sleep onset and maintenance, but 3 mg showed superior maintenance effects in non-elderly adults 5, 3

Option 2: Switch to Alternative Pharmacotherapy

If increasing eszopiclone is not preferred, consider switching to:

Suvorexant (orexin receptor antagonist): Moderate-quality evidence shows improved treatment response and sleep outcomes, particularly for sleep maintenance 1

Low-dose doxepin: Moderate evidence for improved Insomnia Severity Index scores and sleep outcomes, particularly effective for sleep maintenance 1, 6

Zolpidem extended-release: Can address both sleep onset and maintenance 6

Critical Safety Considerations

Age-Related Concerns

At 63 years, this patient is approaching the age threshold where hypnotic risks increase substantially. The guidelines emphasize:

• Use the lowest effective dose, especially in elderly patients 2
• Observational studies link hypnotics to dementia, serious injury, and fractures 1
• FDA warnings include daytime impairment, sleep-driving, behavioral abnormalities, and worsening depression 1, 2

Duration of Pharmacotherapy

FDA approval is for short-term use (4-5 weeks) 1. The guidelines state: "Evidence is insufficient to evaluate the balance of benefits and harms of long-term use of pharmacologic treatments" 1. If insomnia persists beyond 7-10 days of treatment, further evaluation for underlying conditions is warranted 2.

Contraindications to Dose Escalation

Do not increase eszopiclone if the patient:

• Takes alcohol or other CNS depressants concurrently 2
• Has severe hepatic impairment (should remain at 1 mg) 2
• Takes potent CYP3A4 inhibitors (maximum 2 mg) 2
• Has experienced complex sleep behaviors (sleep-driving, sleep-eating) 2

Recommended Algorithm

Step 1: Initiate or refer for CBT-I immediately (strong recommendation) 1

• Components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education
• Can be delivered via telehealth or digital platforms if in-person unavailable

Step 2: While awaiting CBT-I or if adjunctive therapy needed:

• Increase eszopiclone to 3 mg nightly (taken immediately before bed, not after meals) 2
• Use shared decision-making discussing benefits, harms, and costs 1

Step 3: Reassess after 1-2 weeks:

• If improved: Continue combination therapy, plan medication taper once CBT-I effects established
• If no improvement: Consider switching to suvorexant or low-dose doxepin
• If worsening or adverse effects: Discontinue medication, intensify CBT-I

Step 4: Evaluate for underlying conditions if insomnia persists:

• Sleep apnea, restless legs syndrome, depression, anxiety, pain syndromes
• Medication review for insomnia-inducing drugs
• Medical conditions (thyroid, cardiac, pulmonary)

Common Pitfalls to Avoid

1. Continuing ineffective monotherapy: Don't simply continue eszopiclone 2 mg indefinitely without adding CBT-I or adjusting treatment 1

2. Skipping behavioral interventions: Pharmacotherapy alone is not guideline-concordant first-line treatment 1

3. Ignoring rebound insomnia: One study showed rebound effects with eszopiclone 2 mg discontinuation; taper gradually when stopping 1

4. Combining with alcohol or other sedatives: Significantly increases risk of complex sleep behaviors and CNS depression 2

5. Taking after meals: High-fat meals reduce absorption and effectiveness for sleep latency 2